David Bonita Biography and Net Worth

Director of Prelude Therapeutics

David P. Bonita, M.D., has served as a member of Prelude’s Board of Directors since June 2016. Since June 2014, Dr. Bonita has served in various roles at OrbiMed Advisors LLC, an investment firm. Dr. Bonita currently serves on the boards of directors of several public and private companies. He has also worked as a Corporate Finance Analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He received his A.B. in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University.

What is David P. Bonita's net worth?: The estimated net worth of David P. Bonita is at least $57.16 million as of April 21st, 2026. Dr. Bonita owns 11,808,945 shares of Prelude Therapeutics stock worth more than $57,155,294 as of May 7th. This net worth estimate does not reflect any other assets that Dr. Bonita may own. Learn More about David P. Bonita's net worth.
How do I contact David P. Bonita?: The corporate mailing address for Dr. Bonita and other Prelude Therapeutics executives is , , . Prelude Therapeutics can also be reached via phone at 302-467-1280 and via email at [email protected]. Learn More on David P. Bonita's contact information.
Has David P. Bonita been buying or selling shares of Prelude Therapeutics?: During the last ninety days, David P. Bonita has bought $12,499,998.60 in shares of Prelude Therapeutics stock. Most recently, on Tuesday, April 21st, David P. Bonita bought 2,815,315 shares of Prelude Therapeutics stock. The stock was acquired at an average cost of $4.44 per share, with a total value of $12,499,998.60. Following the completion of the transaction, the director now directly owns 11,808,945 shares of the company's stock, valued at $52,431,715.80. Learn More on David P. Bonita's trading history.
Who are Prelude Therapeutics' active insiders?: Prelude Therapeutics' insider roster includes David Bonita (Director), Andrew Combs (EVP), Bryant Lim (CFO), David Mauro (Insider), Deborah Morosini (EVP), Christopher Pierce (EVP), Brian Piper (CFO), and Peggy Scherle (Insider). Learn More on Prelude Therapeutics' active insiders.
Are insiders buying or selling shares of Prelude Therapeutics?: In the last year, Prelude Therapeutics insiders bought shares 2 times. They purchased a total of 5,630,630 shares worth more than $24,999,997.20. The most recent insider tranaction occured on April, 21st when Director David P Bonita bought 2,815,315 shares worth more than $12,499,998.60. Insiders at Prelude Therapeutics own 63.9% of the company. Learn More about insider trades at Prelude Therapeutics.
Information on this page was last updated on 4/21/2026.

David P. Bonita Insider Trading History at Prelude Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/21/2026	Buy	2,815,315	$4.44	$12,499,998.60	11,808,945

David P. Bonita Buying and Selling Activity at Prelude Therapeutics

Prelude Therapeutics Company Overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Today's Range

Now: $4.87

$4.65

$4.88

50 Day Range

MA: $3.73

$2.63

$5.52

2 Week Range

Now: $4.87

$0.75

$5.54

Volume

28,008 shs

Average Volume

395,355 shs

Market Capitalization

$306.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11